pms-FERROUS SULFATE (Ferrous Sulfate Tablets BP) 300 mg
Natural health product licensed in Canada
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Anhydrous Ferrous Sulfate | 187 milligramme | Not calculated |
Non-medicinal ingredients
Cellulose, microcristalline, Starch, Pregelatinized, Eau purifiée, Lactose Monohydrate, Croscarmellose de sodium, Acide citrique anhydre, Stéarate de magnésium, Dioxyde de silicium colloïdal, Hydroxyanisole butylé, Opadry Red
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Comprimé | 1 Tous les jours |
Uses authorised in Canada
A factor in the prevention of iron deficiency.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
There is enough drug in this package to seriously harm a child. Keep out of reach of children. Do not use except under the care of a physician. Consult a healthcare professional prior to use if you are pregnant or breastfeeding, if you have peptic ulcer, regional enteritis, ulcerative colitis. Discontinue and consult a healthcare professional if you experience symptoms of iron toxicity such as nausea, vomiting, abdominal pain, hermatemesis (vomiting of blood) and diarrhea.
- Contre-indications
Hemosiderosis, hemolytic anemia, hemochromatosis
Product record
- Licence holder
- Pharmascience Inc. / Pendopharms, Division of Pharmascience Inc.
- NPN or DIN-HM
- 00586323
- Status
- Active licence
- Licence date
- 3 October 2007
- Revision date
- 27 March 2024
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- DIN de transition
Source
Official Health Canada record, licence 00586323
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “pms-FERROUS SULFATE (Ferrous Sulfate Tablets BP) 300 mg (Pharmascience Inc. / Pendopharms, Division of Pharmascience Inc.): composition and ingredients”, https://compoatlas.com/en/supplements/canada/00586323-pms-ferrous-sulfate-ferrous-sulfate-tablets-bp-300-mg, updated 27 March 2024.